Cedra Appoints New CEO

Thursday, May 13, 2010 07:43 AM

Cedra, a division of Worldwide Clinical Trials (WCT), appointed Anthony Busa, Jr., as its new permanent CEO, replacing Cedra founder David Garcia. Thomas Wardle, chief operating officer of WCT, has served as interim CEO since Garcia stepped down earlier this year.

Busa has 34 years of experience within the pharmaceutical and medical devices industries and has held senior management positions at McClintic Busa Group (a clinical trials consulting firm that Busa co-founded in 1998), Dgd Research, Esoterix, Medsites and Covance.

“[Busa] has a thorough understanding of how this business and industry functions,” Wardle said. “He will be a great asset to our team in terms of growth and management.”   

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs